135 related articles for article (PubMed ID: 12728402)
21. [Lymphoma. Current status and treatment].
Labardini-Méndez JR; Gutiérrez AA; Martínez F; Chávez AD; Morales-Polanco MR; Sobrevilla-Calvo PJ
Gac Med Mex; 2000; 136(3):221-47. PubMed ID: 10893851
[TBL] [Abstract][Full Text] [Related]
22. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation.
Carter RF; Valli VE; Lumsden JH
Can J Vet Res; 1986 Apr; 50(2):154-64. PubMed ID: 3756669
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
24. Non-Hodgkin's lymphoma.
Smith MR
Curr Probl Cancer; 1996; 20(1):6-77. PubMed ID: 8919170
[TBL] [Abstract][Full Text] [Related]
25. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
26. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
27. [Reproducibility and prognostic value of histopathological classifications of malignant lymphomas. Prolegomena for the 1st international classification proposed by WHO. Group of the non-Hodgkin's Malignant Lymphoma Classification Project].
Diebold J; Weisenburger D; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Harris NL; Anderson JR; Roy P; Armitage JO
Bull Acad Natl Med; 1998; 182(7):1537-48; discussion 1548-9. PubMed ID: 9916346
[TBL] [Abstract][Full Text] [Related]
28. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
29. New therapeutic approaches to non-Hodgkin's lymphomas.
Lambert JF; Elfenbein GJ
Med Health R I; 2003 Aug; 86(8):236-9. PubMed ID: 14582217
[No Abstract] [Full Text] [Related]
30. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index.
Janssen-Heijnen ML; van Spronsen DJ; Lemmens VE; Houterman S; Verheij KD; Coebergh JW
Br J Haematol; 2005 Jun; 129(5):597-606. PubMed ID: 15916681
[TBL] [Abstract][Full Text] [Related]
31. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.
Daum S; Ullrich R; Heise W; Dederke B; Foss HD; Stein H; Thiel E; Zeitz M; Riecken EO
J Clin Oncol; 2003 Jul; 21(14):2740-6. PubMed ID: 12860953
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic factors and predictive model of non-Hodgkin's lymphoma: pathological prognostic groupings and international prognostic index].
Shimoyama M
Nihon Rinsho; 2000 Mar; 58(3):602-11. PubMed ID: 10741132
[TBL] [Abstract][Full Text] [Related]
33. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
35. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?
Fernandez HF; Escalón MP; Pereira D; Lazarus HM
Bone Marrow Transplant; 2007 Sep; 40(6):505-13. PubMed ID: 17589535
[TBL] [Abstract][Full Text] [Related]
36. [Classification of malignant lymphomas--current status and clinical implications].
Hiddemann W
Ther Umsch; 1996 Nov; 53(11):816-9. PubMed ID: 8984686
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients.
Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S
Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974
[TBL] [Abstract][Full Text] [Related]
38. [Rituximab].
Okamoto R; Maeda Y; Sasaki T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
[TBL] [Abstract][Full Text] [Related]
39. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
Shome D; Esmaeli B
Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
[TBL] [Abstract][Full Text] [Related]
40. Classification and clinical course of low-grade non-Hodgkin's lymphomas with overview of therapy.
Vose JM
Ann Oncol; 1996; 7 Suppl 6():S13-9. PubMed ID: 9010574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
